Randomized trial of thymoglobulin [antithymocyte globulin] induction, initial tacrolimus, and mycophenolate mofetil therapy with steroid avoidance in primary kidney transplant recipients followed by continued tacrolimus/mycophenolate mofetil therapy vs. sirolimus/mycophenolate mofetil therapy.

Trial Profile

Randomized trial of thymoglobulin [antithymocyte globulin] induction, initial tacrolimus, and mycophenolate mofetil therapy with steroid avoidance in primary kidney transplant recipients followed by continued tacrolimus/mycophenolate mofetil therapy vs. sirolimus/mycophenolate mofetil therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Sirolimus (Primary) ; Mycophenolate mofetil; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jul 2012 Additional lead trial centre (Pfizer) added as reported by ClinicalTrials.gov record.
    • 02 Feb 2010 Actual end date (Sep 2008) added reported by ClinicalTrials.gov.
    • 02 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top